簡介:阿德福韋酯片,Adefovir Dipivoxil可阻斷HBV逆轉(zhuǎn)錄酶。
阿德福韋酯片物理化學(xué)性質(zhì):
密度 |
1.4±0.1 g/cm3 |
沸點 |
641.0±65.0 °C at 760 mmHg |
熔點 |
98-102oC |
分子式 |
C20H32N5O8P |
分子量 |
501.47 |
閃點 |
341.5±34.3 °C |
精確質(zhì)量 |
501.198853 |
PSA |
176.79 |
LogP |
2.45 |
蒸汽壓 |
0.0±1.9 mmHg at 25°C |
折射率 |
1.569 |
儲存條件 |
?20°C |
阿德福韋酯片詳細(xì)介紹:
中文名稱: |
阿德福韋酯片 |
中文別名: |
阿德福韋酯片;9-[2-[雙(新戊酰氧基)甲氧基]磷酰甲氧基]乙基-腺嘌呤;阿德伏韋酯;阿德幅韋二脂;阿地福韋雙吡呋酯;阿的福韋酯;阿地福韋酯;阿德福韋酯;9-[2-[雙(新戊酰氧基)甲氧基]磷;Adefovir Dipivoxil 阿德福韋酯;阿達(dá)帕林;阿德伏韋酯,阿德福韋酯,阿德福韋酯片;阿德福韋脂;阿德福韋脂(ADV);培美曲塞二鈉;9-[2-[二(特戊酰氧基)甲基]氧膦基]甲氧基]乙基]腺嘌呤 中文同義詞: 阿德福韋酯;阿地福 |
英文名稱: |
Adefovir dipivoxil |
英文別名: |
Adefovir Dipivoxyl;9-[2-[bis[(pivaloyloxy)methoxy]phosphinyl]methoxy]ethyl]adenine;ADEFOVIR PIVOXIL;BIS(PIVALOYLOXYMETHYL)-9-[2-(PHOSPHONOMETHOXY)ETHYL]ADENINE;BIS POM PMEA;Bis(Pivaloyloxymethyl)-9-[(R)-2-(Phosphonomethoxy)Ethyl]Adenine;Adefovir Dipivoxl;ADEFOVIR DIPVOXIL;ADEFOVIR DIPIVOLIX;ADEFOVIR;PHARMA-0062;Adefovir Dipivoxil;((((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphoryl)-bis(oxy))bis(methylene) bis(2,2-dimethylpropanoate);GS 0840;9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine;9-[2-[Bis(pivaloyloxymethoxy)phosphorylmethoxy]ethyl]adenine;Adefovir Dipivoxi;Hepsera;Preveon;bis-POM PMEA;Adefovirdipivoxl;GS 840;[2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate;C20H32N5O8P;Adefovir dipivoxil [USAN];Adefovir dipivoxil (USAN);U6Q8Z01514;Adefovir Dipivoxil (Preveon, Hepsera);(((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate;NCGC |
CAS號: |
142340-99-6 |
分子式: |
C20H32N5O8P |
分子量: |
501.47 |
詳細(xì)描述: |
博飛美科提供142340-99-6,阿德福韋酯片,Adefovir Dipivoxil,Perfemiker,上海現(xiàn)貨。 Perfemiker,致力于提供高品質(zhì)、高性價比小分子化合物的產(chǎn)品。 Perfemiker小分子化合物大量庫存,提供超過2萬種的抑制劑、激動劑、拮抗劑等產(chǎn)品,是藥物及疾病研究的重要原料供應(yīng)商。 逆轉(zhuǎn)錄酶抑制劑,Adefovir Dipivoxil可阻斷HBV逆轉(zhuǎn)錄酶。 查詢關(guān)鍵詞:“142340-99-6,阿德福韋酯片,Adefovir Dipivoxil,Perfemiker,上?,F(xiàn)貨”。 |
阿德福韋酯片參考文獻(xiàn):
[1]. Marcellin, P., et al., Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003. 348(9): p. 808-16.
[2]. Manolakopoulos, S., et al., Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther, 2008. 27(3): p. 266-73.
[3]. Committee, A.I.S., A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med, 2002. 3(4): p. 229-38.
[4]. Fisher, E.J., et al., The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS, 2001. 15(13): p. 1695-700.